Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer
Menée sur 268 patients atteints d'un cancer du poumon non à petites cellules de stade avancé (âge : 31 à 87 ans), cette étude évalue l'association entre le rapport "volume plaquettaire moyen / nombre de plaquettes" et la survie globale des patients
Background : Mean platelet volume (MPV) is a platelet volume index. Classically, MPV was recognized as a hallmark of platelet activation. Recent studies have revealed that the MPV and MPV/platelet count (PC) ratio can predict long-term mortality in patients with ischemic cardio-vascular disease. In addition, these indices were correlated with the pathophysiological characteristics of patients with various disorders, including malignant tumors.
Patients and methods : We retrospectively analyzed various hematological indices of patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the contribution of platelet volume indices to survival in these patients.
Results : A total of 268 patients were enrolled in the study. The median age of the patients was 68 years (range: 31–87 years). We compared various hematological indices between the NSCLC group and an age- and sex-matched comparator group. MPV was significantly decreased in the NSCLC group compared to the comparator group. In contrast, the PC was significantly increased in the NSCLC group. Consequently, the MPV/PC ratio was also decreased in the NSCLC group (0.397 vs. 0.501). In receiver operating characteristics (ROC) curve analysis, the MPV/PC ratio was associated with a sensitivity of 62.3% and a specificity of 74.6% at a cutoff value of 0.408730 (area under the curve [AUC], 0.72492)]. Univariate analysis revealed that overall survival (OS) was significantly shorter in the group with a low MPV/PC ratio than in the other group (median survival time [MST]: 10.3 months vs. 14.5 months, log-rank, P = 0.0245). Multivariate analysis confirmed that a low MPV/PC ratio was an independent unfavorable predictive factor for OS (hazard ratio [HR]: 1.668, 95% confidence interval [CI]: 1.235 to 2.271, P = 0.0008).
Conclusion: These data clearly demonstrate that the MPV/PC ratio was closely associated with survival in patients with advanced NSCLC.
Lung Cancer , résumé, 2012